L3VLUP
ProSign in

TGTX · VRTX in the 13F filings

Two to four stocks side by side among the 95 tracked managers: who lists them, how that has moved, who bought and sold in a quarter, and which managers hold more than one.

TGTXVRTX
Quarter
Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023

Holders over time

Tracked managers listing each stock every quarter, at least, or their combined reported value. A gap is a quarter in which no tracked manager listed it. Click a quarter to compare there.
  • TGTX
  • VRTX
010203040202120222023202420252026
Holders and value by quarter
QuarterTGTXVRTX
Q3 20203 holders, $416m31 holders, $21.9bn
Q4 20207 holders, $1.3bn30 holders, $18.4bn
Q1 20216 holders, $1.4bn31 holders, $15.4bn
Q2 20216 holders, $1.2bn30 holders, $12.7bn
Q3 20214 holders, $893m35 holders, $10.1bn
Q4 20212 holders, $194m28 holders, $12.4bn
Q1 20222 holders, $74m23 holders, $16.1bn
Q2 20222 holders, $29m25 holders, $18.1bn
Q3 20222 holders, $51m22 holders, $18.4bn
Q4 20225 holders, $108m28 holders, $18.4bn
Q1 20233 holders, $55m26 holders, $21.4bn
Q2 20237 holders, $154m27 holders, $24.7bn
Q3 20235 holders, $47m33 holders, $24.3bn
Q4 20232 holders, $36m32 holders, $28.6bn
Q1 20243 holders, $37m31 holders, $29.8bn
Q2 20246 holders, $109m29 holders, $33.4bn
Q3 20246 holders, $94m27 holders, $33.5bn
Q4 20243 holders, $2.7m26 holders, $28.5bn
Q1 20255 holders, $57m21 holders, $35.4bn
Q2 20254 holders, $49m21 holders, $32.3bn
Q3 20256 holders, $102m22 holders, $25.9bn
Q4 20256 holders, $83m26 holders, $31.8bn
Q1 20265 holders, $88m25 holders, $31.8bn
Q2 20268 holders, $445m26 holders, $34.6bn
TGTX

TG Therapeutics Inc

Holders
8
Reported value
$445m
Buyers
21
Sellers
10

Breadth +11 among 91 comparable managers.

Pharmaceuticals and biotechnologyHealthcare: biopharma and medtech · L3VLUPPharmaceutical preparations
VRTX

Vertex Pharmaceuticals Inc

Holders
26
Reported value
$34.6bn
Buyers
21
Sellers
17

Breadth +4 among 91 comparable managers.

Pharmaceuticals and biotechnologyHealthcare: biopharma and medtech · L3VLUPPharmaceutical preparations

Who holds both, Q2 2026

Among the 30 tracked managers listing any of them. "Only" is about listed positions: a manager may hold the other below its listed range.

Only TGTX (4)

D. E. Shaw & Co., ExodusPoint Capital Management LP, PDT Partners LLC, Walleye Capital LLC

Only VRTX (22)

Acadian Asset Management LLC, AllianceBernstein LP, AQR Capital Management LLC, Arrowstreet Capital LP, Baillie Gifford & Co, Balyasny Asset Management LLC, Brevan Howard Capital Management LP, Capital Research Global Investors, Capital World Investors, Citadel Advisors LLC, Fidelity (FMR LLC), Holocene Advisors LP, Hudson Bay Capital Management LP, Invesco Ltd, Janus Henderson Group Ltd, Man Group PLC, Marshall Wace LLP, MFS Investment Management, Millennium Management LLC, Neuberger Berman Group LLC, T. Rowe Price Associates Inc, Wellington Management Group LLP

How much of the picture this is

A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. Buyers and sellers count comparable managers (those that filed both quarters) by shares, so a rise in value with no rise in shares is the price. Large books are listed to their largest positions. These are 95 tracked managers, not the institutional market.

Back to the 13F Explorer →